Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China
文献类型:期刊论文
作者 | Xu, Chunwei48,49; Si, Lu50; Wang, Wenxian51; Li, Ziming52; Song, Zhengbo51; Wang, Qian53; Liu, Aijun54; Yu, Jinpu55; Fang, Wenfeng56; Zhong, Wenzhao57 |
刊名 | THORACIC CANCER |
出版日期 | 2022-09-20 |
ISSN号 | 1759-7706 |
关键词 | fusion precision medicine solid tumor targeted therapy tyrosine receptor kinase |
DOI | 10.1111/1759-7714.14644 |
通讯作者 | Zhang, Xiaotian(zhangxiaotianmed@163.com) ; Song, Yong(yong.song@nju.edu.cn) ; Lu, Yuanzhi(yuanzhi.lu@jnu.edu.cn) |
英文摘要 | Gene fusions can drive tumor development for multiple types of cancer. Currently, many drugs targeting gene fusions are being approved for clinical application. At present, tyrosine receptor kinase (TRK) inhibitors targeting neurotrophic tyrosine receptor kinase (NTRK) gene fusions are among the first "tumor agnostic" drugs approved for pan-cancer use. Representative TRK inhibitors, including larotrectinib and entrectinib, have shown high efficacy for many types of cancer. At the same time, several second-generation drugs designed to overcome first-generation drug resistance are undergoing clinical development. Due to the rarity of NTRK gene fusions in common cancer types and technical issues regarding the complexity of fusion patterns, effectively screening patients for TRK inhibitor treatment in routine clinical practice is challenging. Different detection methods including immunohistochemistry, fluorescence in situ hybridization, reverse transcription-polymerase chain reaction, and (DNA and/or RNA-based) next-generation sequencing have pros and cons. As such, recommending suitable tests for individual patients and ensuring the quality of tests is essential. Moreover, at present, there is a lack of systematic review for the clinical efficacy and development status of first- and second-generation TRK inhibitors. To resolve the above issues, our expert group has reached a consensus regarding the diagnosis and treatment of NTRK gene fusion solid tumors, aiming to standardize clinical practice with the goal of benefiting patients with NTRK gene fusions treated with TRK inhibitors. |
WOS关键词 | INFANTILE FIBROSARCOMA ; MESOBLASTIC NEPHROMA ; MOLECULAR-DETECTION ; ANCHORED MULTIPLEX ; KINASE ; EXPRESSION ; MUTATIONS ; FAMILY ; INHIBITION ; RECEPTORS |
WOS研究方向 | Oncology ; Respiratory System |
语种 | 英语 |
出版者 | WILEY |
WOS记录号 | WOS:000855706000001 |
源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/128990] |
专题 | 中国科学院合肥物质科学研究院 |
通讯作者 | Zhang, Xiaotian; Song, Yong; Lu, Yuanzhi |
作者单位 | 1.Tianjin Med Univ Canc Inst & Hosp, Dept Integrat Oncol, Tianjin, Peoples R China 2.Xiamen Univ, Affiliated Hosp Med 1, Dept Med Oncol, Xiamen, Peoples R China 3.China Med Univ, Dept Med Oncol, Canc Hosp, Shenyang, Peoples R China 4.Univ Chinese Acad Sci, Zhejiang Key Lab Radiat Oncol, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China 5.Univ Elect Sci & Technol, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med, Chengdu, Peoples R China 6.Fudan Univ, Dept Radiat Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China 7.Peking Univ Canc Hosp & Inst, Dept Radiat Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China 8.Natl Clin Res Ctr Digest Dis, State Key Lab Canc Biol, Xian, Peoples R China 9.Fourth Mil Med Univ, Natl Clin Res Ctr Digest Dis, State Key Lab Canc Biol, Xian, Peoples R China 10.Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian, Peoples R China |
推荐引用方式 GB/T 7714 | Xu, Chunwei,Si, Lu,Wang, Wenxian,et al. Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China[J]. THORACIC CANCER,2022. |
APA | Xu, Chunwei.,Si, Lu.,Wang, Wenxian.,Li, Ziming.,Song, Zhengbo.,...&Lu, Yuanzhi.(2022).Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China.THORACIC CANCER. |
MLA | Xu, Chunwei,et al."Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China".THORACIC CANCER (2022). |
入库方式: OAI收割
来源:合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。